(E)-3-苯乙烯基-5-甲基-1,2,4-恶二唑 | 129610-15-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (E)-3-苯乙烯基-5-甲基-1,2,4-恶二唑
• 英文名称: (E)-5-methyl-3-styryl-1,2,4-oxadiazole
• 英文别名: 5-methyl-3-[(E)-2-phenylethenyl]-1,2,4-oxadiazole
• CAS: 129610-15-7
• 化学式: C₁₁H₁₀N₂O
• 分子量: 186.213
• InChiKey: FUVDZQFKRKLVKZ-BQYQJAHWSA-N

物化性质

• 熔点：
  78 °C
• 沸点：
  330.6±35.0 °C(Predicted)
• 密度：
  1.177±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-3-苯乙烯基-5-甲基-1,2,4-恶二唑 生成 (Z)-3-styryl-5-methyl-1,2,4-oxadiazole
  参考文献：
  名称：

  BUSCEMI, SILVESTRE;CUSMANO, GIUSEPPE;GRUTTADAURIA, MICHELANGELO, J. HETEROCYCL. CHEM., 27,(1990) N, C. 861-863

  摘要：

  DOI：
• 作为产物：
  描述：

  (肉)桂腈 在 乙醇 、 盐酸羟胺 、 sodium carbonate 作用下， 生成 (E)-3-苯乙烯基-5-甲基-1,2,4-恶二唑
  参考文献：
  名称：

  Wolff, Chemische Berichte, 1886, vol. 19, p. 1509

  摘要：

  DOI：

文献信息

• Preparation, structure, and versatile reactivity of pseudocyclic benziodoxole triflate, new hypervalent iodine reagent
  作者：Akira Yoshimura、Khiem C. Nguyen、Scott C. Klasen、Akio Saito、Victor N. Nemykin、Viktor V. Zhdankin

  DOI：10.1039/c5cc02009c

  日期：——

  A new pseudocyclic triflate derivative of benziodoxole (IBA-OTf) was prepared and characterized by a single crystal X-ray analysis. This new, highly electrophilic hypervalent iodine reagent readily reacts with various nucleophilic...

  制备了新的苯并吲哚的拟环三氟甲磺酸衍生物（IBA-OTf），并通过单晶X射线分析对其进行了表征。这种新型的高度亲电的高价碘试剂可轻松与各种亲核试剂反应...
• Rhodium(III)-Catalyzed Oxadiazole-Directed Alkenyl C–H Activation for Synthetic Access to 2-Acylamino and 2-Amino Pyridines
  作者：Fan Yang、Jiaojiao Yu、Yun Liu、Jin Zhu

  DOI：10.1021/acs.joc.7b01303

  日期：2017.10.6

  We report herein a Rh(III)-catalyzed alkenyl C–H activation protocol for the coupling of oxadiazoles with alkynes and synthesis of 2-acylamino and 2-amino pyridines, an important heterocyclic scaffold for various naturals products and synthetic pharmaceuticals bearing a readily reacting functional group. The selective protection/deprotection of amino groups through simple solvent switching, good functional

  我们在此报告Rh（III）催化的恶二唑与炔烃的偶联和2-酰基氨基和2-氨基吡啶的合成的Rh（III）催化的烯基C–H活化协议，这是各种天然产物和带有易于反应的合成药物的重要杂环骨架功能小组。通过简单的溶剂转换，良好的官能团相容性，优异的产物收率和高的区域选择性对氨基进行的选择性保护/脱保护是该反应方案中见证的一些明显的合成特征。
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSES HETEROCYCLIQUES ET PROCEDES D'UTILISATION DE CEUX-CI
  申请人：MERCK & CO INC

  公开号：WO2001016121A1

  公开（公告）日：2001-03-08

  In accordance with the present invention, there are provided novel class of heterocyclic compounds and methods of use thereof. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. At a ring position adjacent to a ring nitrogen atom, the heterocyclic ring has at least one substituent which includes a moiety, linked to the heterocyclic ring via an alkylene moiety, an alkynylene moiety or an azo group. Invention compounds are capable of a wide variety of uses including modulating physiological processes by functioning as agonists and antagonists of receptors in the nervous system, as insecticides, and as fungicides. The invention further provides methods of modulating the activity of excitatory amino acid receptors using a specifically defined class of heterocyclic compounds including the novel compounds referred to above. In one embodiment, there are provided methods of modulating metabotropic glutamate receptors. The present invention also discloses methods of treating disease using heterocyclic compounds. The invention further discloses methods of preventing disease conditions related to diseases of the pulmonary system, diseases of the nervous system, diseases of the cardiovascular system, diseases of the gastrointestinal system, diseases of the endocrine system, diseases of the exocrine system, diseases of the skin, cancer and diseases of the ophthalmic system. The invention also discloses pharmaceutically acceptable salt forms of the above-described heterocyclic compounds.

  根据本发明，提供了一类新型的杂环化合物及其使用方法。该发明的化合物包含一个取代的、不饱和的五、六或七元杂环环，其中至少包含一个氮原子和至少一个碳原子。在靠近环氮原子的环位置上，杂环环有至少一个取代基，包括一个官能团，通过烷基官能团、炔基官能团或偶氮基团连接到杂环环上。发明的化合物能够广泛应用，包括通过作为神经系统受体的激动剂和拮抗剂来调节生理过程，作为杀虫剂和杀菌剂。本发明还提供了使用特定定义的杂环化合物类来调节兴奋性氨基酸受体活性的方法，包括上述新型化合物。在一种实施例中，提供了调节代谢性谷氨酸受体的方法。本发明还揭示了使用杂环化合物治疗疾病的方法。本发明还揭示了预防与肺系统疾病、神经系统疾病、心血管系统疾病、胃肠系统疾病、内分泌系统疾病、外分泌系统疾病、皮肤疾病、癌症和眼科系统疾病相关的疾病状态的方法。本发明还揭示了上述杂环化合物的药物可接受的盐形式。
• Methods of modulating processes mediated by excitatory amino acid receptors
  申请人：Cosford Nicholas D. P.

  公开号：US06956049B1

  公开（公告）日：2005-10-18

  In accordance with the present invention, there are provided methods of modulating the activity of excitatory amino acid receptors using a specifically defined class of heterocyclic compounds. In one embodiment, there are provided methods of modulating metabotropic glutamate receptors. The present invention also discloses methods of treating disease using heterocyclic compounds. Diseases contemplated include cerebral ischemia, chronic neurodegeneration, psychiatric disorders, schizophrenia, mood disorders, emotion disorders, disorders of extrapyramidal motor function, obesity, disorders of respiration, motor control and function, attention deficit disorders, concentration disorders, pain disorders, neurodegenerative disorders, epilepsy, convulsive disorders, eating disorders, sleep disorders, sexual disorders, circadian disorders, drug withdrawal, drug addiction, compulsive disorders, anxiety, panic disorders, depressive disorders, skin disorders, retinal ischemia, retinal degeneration, glaucoma, disorders associated with organ transplantation, asthma, ischemia and astrocytomas. The invention further discloses methods of preventing disease conditions related to diseases of the pulmonary system, diseases of the nervous system, diseases of the cardiovascular system, diseases of the gastrointestinal system, diseases of the endocrine system, diseases of the exocrine system, diseases of the skin, cancer and diseases of the ophthalmic system. The invention also discloses pharmaceutically acceptable salt forms of heterocyclic compounds.

  根据本发明，提供了使用一类特定定义的杂环化合物来调节兴奋性氨基酸受体活性的方法。在一种实施例中，提供了调节代谢型谷氨酸受体的方法。本发明还揭示了使用杂环化合物治疗疾病的方法。所考虑的疾病包括脑缺血、慢性神经退行性疾病、精神障碍、精神分裂症、情绪障碍、运动功能外围疾病、肥胖症、呼吸、运动控制和功能障碍、注意力缺陷障碍、注意力障碍、疼痛障碍、神经退行性疾病、癫痫、惊厥性障碍、进食障碍、睡眠障碍、性障碍、昼夜节律障碍、药物戒断、药物成瘾、强迫障碍、焦虑、恐慌障碍、抑郁障碍、皮肤疾病、视网膜缺血、视网膜退化、青光眼、与器官移植相关的疾病、哮喘、缺血和星形细胞瘤。本发明还揭示了杂环化合物的药物可接受的盐形式的方法。
• Reactions of thianthrene cation radical with oximes of cinnamaldehydes and unsaturated aromatic ketones in acetonitrile
  作者：A. K. M. M. Hoque、Wang Keun Lee、Henry J. Shine、Da Chuan Zhao

  DOI：10.1021/jo00003a084

  日期：1991.2